PQT
The Setup
PQT Health
Issue live · 2026-11-11
Week of November 9, 2026 · Healthcare Weekly Brief
Humana Up 7%, Centene Fades as Rates Retake Healthcare's Wheel
A week after the midterm sweep, earnings and a 5% 10-year yield, not Congress, are setting healthcare prices.
01
The Setup
The forces shaping this week's market
A week after Democrats won both chambers, healthcare stocks traded on earnings and rates rather than policy. XLV closed Nov 11 at $188.98, down 0.4% from Nov 4, after a 2.5% drop in the Nov 5 AI-led selloff. Humana rose 7.0% on a cost beat and guidance raise; Centene gave back 7.3% as hopes for ACA subsidies before 2027 enrollment faded. October CPI showed hospital services up 0.8%, and the 10-year yield returned to about 5%.
01
Rates Retake Control
Core CPI rose 0.3% again and hospital prices 0.8%. The 10-year is back near 5% and December hike odds hit about 84%.
02
Humana Wins Earnings
A 93.7% benefit ratio beat guidance and FY EPS rose to at least $9.50. HUM is up 7.0% since Nov 4; Cigna faded from $318.
03
Subsidy Trade Unwinds
Centene fell 7.3% as Congress returned with Dec 11 funding and a Dec 15 enrollment deadline it cannot meet.
02
Scorecard
Who wins, who is squeezed
▲ Winner
Payers with cost control
- Humana rose 7.0% on a benefit-ratio beat and guidance raise.
- CVS rebounded 11.9% from its post-split close of $79.96.
- Lilly erased its 3.8% Nov 5 drop and sits 1% below its high.
$HUM
$CVS
$LLY
▼ Squeezed
Subsidy and biotech beta
- Centene fell 7.3% from Nov 4 to $70.44.
- XBI dropped 6.7% on Nov 5 and is down 1.8% on the week.
- UnitedHealth fell 1.6%, trailing Humana by almost nine points.
$CNC
$UNH
◆ Mixed
Hospitals and Cigna
- HCA dipped 0.9% but is still 9.3% above its Nov 3 close.
- Cigna raised guidance yet closed 1.3% below Nov 4.
- UHS flagged a $175M-$200M 2027 Medicaid payment headwind.
$HCA
$CI
03
The Numbers
Figures that matter this week
04
Where Prices Sit
Benchmark levels in their 52-week range
Last available snapshots as of 2026-11-11. The marker shows the current price within the 52-week range.
$188.98
$141.97 low
93.4% of range
$192.32 high
Down 0.4% since Nov 4; set a 52-week high of $192.32 on Nov 5 before the 4.4% market drop. Flat Nov 11 while SPY rose 1.3%.
$156.24
$109.28 low
77.5% of range
$169.89 high
Down 1.8% since Nov 4 after a 6.7% drop Nov 5; recovered to within 2% of last week's close.
$402.81
$255.97 low
71.4% of range
$461.62 high
Down 1.6% since Nov 4 and 0.6% Nov 11; lagging Humana by almost 9 points on the week.
05
Equity Watch
Names in focus this week
Filter
Sort
| Ticker | Company | Sector | Direction | Key Catalyst |
|---|---|---|---|---|
HUM$446.59 |
Humana | Managed Care | ▲ Bullish, guide raised |
FY26 adj EPS guide raised to at least $9.50; 93.7% Q3 benefit ratio beat guidance+ WHY IT MATTERS |
CVS$89.46 |
CVS Health | Payers | ◆ Mixed, sharp rebound |
Split plan still lacks financials; 2027 adj EPS at least $8.65+ WHY IT MATTERS |
CNC$70.44 |
Centene | Managed Care | ▼ Bearish, election rally faded |
ACA subsidy restoration cannot pass before the Dec 15 enrollment deadline+ WHY IT MATTERS |
LLY$1,437.76 |
Eli Lilly | Pharma | ▲ Bullish, recovered selloff |
Novo cuts US Wegovy/Ozempic list prices to as low as $675 on Jan 1+ WHY IT MATTERS |
CI$301.43 |
The Cigna Group | Payers | ◆ Mixed, beat then faded |
2026 adj EPS raised to at least $30.60; 10%-14% long-term EPS CAGR target+ WHY IT MATTERS |
UNH$402.81 |
UnitedHealth Group | Managed Care | ◆ Mixed, lagging peers |
2027 Stars and MA margin repair; Democratic oversight of prior authorization+ WHY IT MATTERS |
HCA$505.87 |
HCA Healthcare | Providers | ◆ Mixed, holding gains |
About $400M quarterly EBITDA hit from marketplace-to-uninsured shift persists into Q1+ WHY IT MATTERS |
06
One-Week Scenarios
One-week outlook: November 11 - November 18, 2026
Probabilities are analytical judgments. Price ranges are illustrative, not forecasts. Hover a band to isolate its case.
BASE 50%BULL 20%BEAR 30%50%
Base caseRange trade on rates
Yields hold between 4.9% and 5.1%, Nov 14 FDA decisions land mostly as expected and CR talks stay vague. Payers trade on earnings follow-through; XLV stays inside its post-election range.
XLV $185-$192
XBI $151-$160
UNH $395-$412
20%
Bull caseDefensives regain favor
Yields ease, AI momentum cools and money rotates back to healthcare. Talk of a subsidy bridge in the CR lifts hospitals and Centene; XLV retests $192.
XLV $191-$196
XBI $159-$166
UNH $410-$424
30%
Bear caseHike priced, risk-off returns
Fed speakers lock in a December hike and the 10-year tops 5.1%. Another AI-led selloff hits like Nov 5, biotech leads the drop and subsidy names lose the rest of the election rally.
XLV $179-$186
XBI $144-$152
UNH $384-$398
07
The Intelligence Take
What the market is missing
Analyst assessment
Trade earnings and rates, not the election: favor payers proving cost control like Humana, keep hospitals on earnings support, and stay underweight subsidy-dependent names until a funding bill actually carries ACA money.
01The market has stopped paying for policy it cannot see. Last week's rally bought an option on ACA and Medicaid relief; this week it marked that option down where it was purest (Centene) and kept it where earnings back it up (HCA, backed by UHS's 4.9% admissions growth and a 0.8% October jump in hospital prices). The calendar is the problem: Dec 11 funding, Dec 15 enrollment, Jan 1 physician pay cliff and Jan 3 new Congress all arrive before a Democratic bill can reach a desk that has a veto pen.
02In managed care, medical cost trend is the only scoreboard that matters, and Humana just won a round. A 93.7% benefit ratio below guidance after two years of MA cost overruns explains why it outran UnitedHealth by almost nine points. Cigna shows the other side: a raise that came with a 22% drop in pharmacy benefit services income, which is exactly where PBM reform and the new DOL rule bite.
03Drug pricing risk eased at the margin. CMS cut the GLOBE most-favored-nation model to about four manufacturers and $440 million in savings, and the IRA final rule mostly codified existing policy with a temporary price floor for small biotechs. The bigger pricing story is commercial: Novo cuts US Wegovy and Ozempic list prices to as low as $675 on Jan 1. That pressures obesity margins more than anything Washington did this month. With rates near 5% and the market rotating back into AI, healthcare is acting as a funding source, not a haven.
08
Confirmed Facts
What we know with high confidence
- ✓Humana raised 2026 adjusted EPS guidance to at least $9.50 on Nov 6 after a 93.7% Q3 insurance benefit ratio.
- ✓Cigna raised 2026 adjusted EPS to at least $30.60 on Nov 5; Q3 revenue was $73.7B and adj EPS $7.98.
- ✓October CPI: core +0.3%, medical care +0.3%, hospital services +0.8%, physicians' services +0.4% month over month (BLS, Nov 10).
- ✓FDA approved Bayer's Sunharbo (asundexian) on Nov 9 for secondary stroke prevention, the 48th novel approval of 2026.
- ✓CMS finalized the IRA negotiation rule for 2029+ on Nov 5; the GLOBE MFN model starts Jan 1, 2027 at about $440M in projected savings.
09
Risks & Watch
What could break the thesis
- !A December CR that extends funding without ACA subsidies would confirm the 2027 premium shock and hit exchange-heavy payers and hospitals.
- !Ten-year yields above 5.1% and a priced-in December hike would weigh most on XBI, which fell 6.7% in one session Nov 5.
- !Novo's Jan 1 list-price cuts could force Lilly to respond and compress GLP-1 pricing.
- !Nov 14 FDA decisions on ivonescimab, aficamten and Igalmi are binary for Summit and Cytokinetics.
10
Key Dates & Catalysts
The calendar ahead
11
Regulatory Landscape
CMS, FDA, and legislative status
FDA
FDA Status
FDA approved Bayer's Sunharbo (asundexian) Nov 9, the first factor XIa inhibitor in the US, for stroke prevention after a non-cardioembolic ischemic stroke or high-risk TIA; it is the 48th novel approval of 2026. J&J's subcutaneous Rybrevant Faspro won accelerated approval in head-and-neck cancer. Nov 14 brings decisions on ivonescimab, aficamten and Igalmi. Commissioner nominee Heidi Overton awaits a Senate vote.
CMS
CMS Status
CMS issued the IRA negotiation final rule Nov 5 for 2029 and later, mostly codifying policy and adding a temporary price floor for small-biotech drugs. The GLOBE most-favored-nation Part B model starts Jan 1, 2027, scaled down to about four manufacturers and $440M in savings. CMS plans to remove about 760,000 HealthCare.gov enrollees it found fraudulent or nonexistent.
LEG
Legislative Status
The lame duck runs Nov 9-Dec 11, when government funding expires; another short-term CR is likely. Enhanced ACA subsidies expired after 2025 and cannot be restored before the Dec 15 enrollment deadline; House Democrats plan an early vote in January but face a likely veto. A temporary 2.5% physician fee increase and several extenders expire at year-end.
◆
Sources
All 41 sources
⌕
Showing 12 of 41
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]